Skip to main content

Yikon Genomics Partners With US Fertility Center to Launch Embryo Screening Assay

NEW YORK (GenomeWeb) — Yikon Genomics said today that it has signed an agreement to launch its noninvasive chromosomal screening assay for aneuploidy with the Center for Reproductive Health & Gynecology (CRHG), a Beverly Hills, California-based in vitro fertilization center.

The test uses next-generation sequencing to screen embryos for chromosomal aneuploidy prior to implantation, according to Shanghai-based Yikon. It analyzes in vitro embryo culture medium and does not require a biopsy.

Under the terms of the deal, the companies will make the test available for commercial clinical services through a joint CLIA-certified genetics lab at the CRHG. Additional terms were not disclosed.

"Being able to provide [preimplantation genetic screening] without the need for an embryo biopsy is a gamechanger," CRHG Founder Sam Najmabadi said in a statement. "It allows us to perform genetic testing on embryos with no chance of damage to the embryo. It also allows for a more accurate result overall."

Yikon Genomics was cofounded in 2012 by a Harvard University professor and offers testing in reproductive health and cancer diagnostics.